DHPA

  • Home
  • About Us
    • Leadership
      • Executive Committee
      • Board Members
    • DHPA Members
    • Contact Us
    • Join Us
  • Advocacy
    • Patient Access to Independent GI Care
      • Colorectal Cancer Screening
    • Diversity Equity and Inclusion
    • Modernizing the Stark Law
    • Saving the IOASE
    • Pathology Services Utilization
  • Resources
    • CRC Screening
    • Independent GI Careers
    • Research
    • Fact Sheets
    • Letters to Policymakers
    • Leadership Series
  • Newsroom
    • Press Releases
    • DHPA in the News
    • GI News Round Up
  • Take Action

July 16, 2018

DHPA Submits Comments in Response to HHS RFI on “Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs”

DHPA has submitted comments to the U.S. Health and Human Services Request for Information entitled “Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.”

In the comment letter, DHPA focuses on several of the key initiatives highlighted in the RFI:

  • DHPA supports site neutrality for physician-administered drugs across the hospital and independent physician practice settings in order to promote competition and reduce the overall cost of care for the Medicare system and beneficiaries.
  • DHPA supports reform of the 340B drug discount program to address the program’s anti-competitive nature and to ensure that low-income and uninsured patients benefit from the program.
  • Consistent with the President’s commitment to “put American patients first,” DHPA cannot support a shift of drugs from Medicare Part B to Medicare Part D. Moving drugs from Part B to Part D would not achieve the Administration’s goals of improving health outcomes, lowering out-of-pocket costs, and decreasing total cost of care.
  • For similar reasons, DHPA is concerned about the repercussions of HHS relaunching a Competitive Acquisition Program (“CAP”) for Part B drugs. If such a program were re-introduced, physician participation should be voluntary and substantial guardrails would need to be put in place to ensure that CAP vendors do not interfere in the physician-patient relationship.

Click here to read DHPA’s full comment letter.

Filed Under: Letters to Policymakers, Newsroom, Press Releases, Protecting Patient Access to Integrated GI Care in the Independent Setting

Member Spotlight

Allied Digestive Health is a gastroenterology and hepatology practice with more than 50 locations throughout New Jersey and New York, specializing in colon cancer screening, and the treatment of Celiac Disease, GERD, and IBD.

Learn more at:
www.allieddigestivehealth.com

Become a Member

    Is your practice interested in promoting and preserving accessible, high quality and cost-efficient care in the independent GI medical setting? Contact us today about joining DHPA.

    Recent News

    • Statement on UnitedHealthcare’s Advance Notification Policy for Gastroenterology Services

    • Colorectal Cancer: Am I at Risk? Spanish Translation (Video)

    • The Value of Colonoscopy: The Gold Standard in Colorectal Cancer Screening (Video)

    • Colorectal Cancer: Am I at Risk? (Video)

    • The Value of Colonoscopy (Infographic)

    • Colorectal Cancer: Am I at Risk? (Infographic)

    • Value of Colonoscopy Spanish Translation (Infographic)

    • Colorectal Cancer: Am I at Risk? Spanish Translation (Infographic)

    • DHPA Recommends MACRA Improvements to Bipartisan Group of U.S. Representatives

    Digestive Health Physicians Association, Inc.
    10770 Columbia Pike, Suite 400
    Silver Spring, Maryland, 20901
    © 2020 DHPA

    Follow @DHPAnews
    Tweets by DHPAnews

    Copyright © 2023 · Executive Pro Theme on Genesis Framework · WordPress · Log in